

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 29, 2009 Signature: /David A. Gass #38,153/
(David A. Gass)

Docket No.: 28967/34891.1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/774,802

Confirmation No.: 9059

Filed: February 9, 2004

Art Unit: 1647

Title: (As amended herein) THERAPY TARGETING
FLT4 (VEGFR-3) EXPRESSED IN BLOOD
VESSELS

Examiner: Ian Dang

AMENDMENT IN RESPONSE TO FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

INTRODUCTORY COMMENTS

This paper is timely filed in response to a “final” Office Action dated October 21, 2009, in this matter. Reconsideration is respectfully requested in view of the amendments and remarks that follow.

Amendments to the Specification: None.

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 20 of this paper.